MAPS initiated and funded the clinical research on MDMA-assisted therapy, completed in 2022, that the application builds on. Although MAPS incubated the public-benefit pharmaceutical company, it has ...
U.S. publication of the patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration with Neurothera Labs Inc. as the FDA ...
Roughly 13 million Americans live with PTSD. The FDA has approved only two medications for it, both more than two decades old. The FDA approved sertraline, brand name Zoloft, to treat post-traumatic ...
TEL AVIV, Israel, Aug. 24, 2026 (GLOBE NEWSWIRE)-- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), today announced that its subsidiary, NeuroThera Labs Inc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results